2026 Q1 -tulosraportti
18 päivää sitten
‧43 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 478 | NON | NON | ||
| 1 222 | NON | NON | ||
| 24 | NON | NON | ||
| 1 567 | SSWM | NON | ||
| 109 | NON | NON |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·12 t sittenSell recommendation?
·10 t sittenAre you crazy? I am not selling a single one. Maybe one should buy up and secure an early retirement. 🫡😎
·16 t sittenhttps://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-520105-39-00 uTREAT phase 1: hmm...has the page not been updated with the following information: Estimated end of trial date in EU/EEA: 23/07/2026 Then we might potentially get topline data end of July / beginning of August... ?
·4 t sitten · MuokattuThe Clinical trail dokumentet has been updated via an SM (Substantial Modification). Curasight sent the SM on 27-02-2026 and it was approved on 24-03-2026 (as stated on the front page, cf.. your link) The only thing that has been changed is the Estimated end of trial date in EU/EEA. It has been changed from 15-05-2026 to 27-07-2026. They have thus moved the end date for the GBM Phase I study by a good 2 months. This is due to the expansion of the study from 60 Gy to 100+ Gy and the number of patients from 6 to 12. The first time we heard about the expansion was on 26-02-2026 at the HCA meeting in connection with the annual report (to my knowledge). Here they show a slide describing the expansions and the guided Topline-results mid- 2026. The day after, they send an SM and then guide read-out in Q2 and Topline in Q3. I will not place too much emphasis on the Estimated end of trial date in relation to when Topline results will actually come, as the date is in no way binding! But it gives an indication of what they believed back ultimo Feb. As previously mentioned, I believe mid/ultimo July, especially because they published read-out data 3 weeks before the deadline. And it is a relatively small cohort, so 6-8 weeks should be sufficient for topline data. And it is somewhat in the same direction as they themselves might have had in mind.....but now we have to see. Data is King - we need to see it! ⚡- ·3 päivää sitten · MuokattuI have sent some questions to Curasight based on the timeline from the TD Cowen conference in March. Q. concern the capital requirement wish for 2027, the company's 'catalysts' on the timeline (picture), M&A / Nasdaq elaboration, confirmation of the number of patients for uTREAT Phase 2 (60pers) and Basket trial Phase 1 (up to six persons per indication) etc. The timeline shows a clear strategy, where there is an opportunity to go several ways (but where the highway is called acquisition). I will follow up with answers if I hear from them.·2 päivää sittenSo I quickly got a reply from Ulrich - and on a Sunday too :) And although the answers perhaps leave a lot to be desired, there is still some clarity regarding the - perhaps - upcoming financing, the uTREAT phase 2 / basket trial phase 1 study sizes, etc.. Here are my questions and subsequent answers. (Then you yourselves must assess whether anything useful can be drawn from it or not... :) ) - - - - - Hi Ulrich, Andreas et al. I have now listened to the Q1 presentation at HCA Cap., as well as the TD Cowen presentation a couple of times and now have a couple of questions that I hope you can / are allowed to answer: 1: Is the timeline presented in connection with TD Cowen still valid (see attached image)? -> I.e.: Capital increase ("Fundraising targeted investors USD XXM") comes after topline data for uTREAT phase 1? (I assume it will be a directed issue similar to December 12, 2025) 2:Ulrich; you state in the Q1 presentation that funds need to be raised so that the 2027 plans can be realized. Does the amount only cover uTREAT phase 2, or potentially also Basket trials, phase 1 (+ expenses up to)? (I'm a bit unsure if you only refer to Basket Tr or both programs when you refer in the presentation to "there must be an agreement/(partner) behind the trials"...) 3: TD Cowen presentation: Is the number of patients still correct; i.e. ~60 patients for uTREAT phase 2 and up to 36 patients for Basket Trials, phase 1? 4: TD Cowen presentation: Mid-2027 you mention a catalyst with "M&A and/or Nasdaq listing". If it becomes a Nasdaq listing; Will that mean that you move away from the Spotlight stock exchange and onto a larger one to simultaneously be able to utilize/offer trading via the American stock exchange (will it then be ADR similar to Novo Nordisk??) 5: It seems quite clear that you are focusing/strategizing on being acquired rather than on more partnerships. -> Without going into detail, can you tell if you already have a timely target for when you believe you will be "most valuable"; i.e. when the most opportune time for an acquisition would be? 6: Are you looking into participating in more international conferences later this year? I hope you can answer, if not all, then a couple of the questions. I am quite active in various Curasight forums online (facebook, nordnet, discord) and would like to share your answers, if that's okay with you? Regards Mads - - - Dear Mads, Thank you for your email, your interest in Curasight, and for taking the time to thoroughly review our presentations. I will try to answer your questions within the framework we can communicate publicly. 1 - Timeline and financing: As a general rule, we do not comment on specific timing aspects regarding potential financing transactions beyond what has already been publicly communicated. Our focus remains on creating the greatest possible value through the clinical programs and the expected milestones. 2 - What should future financing cover?: As mentioned in the Q1 presentation, additional capital will primarily be aimed at supporting the company's clinical development plans after the current studies. This includes both further development of the uTREAT® program and potential new clinical initiatives. However, it is too early to comment on the final structure and financing of future studies. 3 - Number of patients in future studies: The patient numbers stated in our latest presentation material still represent our current planning basis. However, final study designs will be determined in dialogue with regulatory authorities and potential collaboration partners. 4 - Nasdaq listing: When we refer to the possibility of a Nasdaq listing, it is a long-term strategic perspective. At present, no decision has been made regarding exchange, structure, or timing, and therefore we cannot comment further on this. 5 - M&A and strategic opportunities: As a listed company, we continuously evaluate all opportunities that can create value for shareholders. This includes partnerships, licensing agreements, financing opportunities, and potential strategic transactions. However, we have not communicated any specific objective or time horizon for a potential corporate transaction. 6 - International conferences: Yes, we continue to expect to participate in relevant international conferences and investor events as our clinical programs develop. Any participations will be communicated via our normal channels. We greatly appreciate the engagement from our shareholders and the many constructive discussions taking place in investor forums. You are naturally welcome to share the above answers, as they are solely based on already publicly disclosed information and general comments. Thank you for your continued support of Curasight – much appreciated. Sincerely / Best regards Ulrich Krasilnikoff CEO – Managing Director Curasight A/S
·1 päivä sittenNice with such competent fellow investors, as well as that you also take the time to inform us others. - ·11.6.🚀 Will a share issue of DKK 20-30 million strengthen the negotiation position? No, Big Pharma knows what it takes to develop a radiopharma platform. They can immediately see through the intention behind a small share issue. The most interesting thing is actually not the share issue, but what Ulrich said about the capital needs in H2: "...of course we will ensure, when we talk about new studies and other things, that there is an agreement behind it of one kind or another, that can carry it through." He is not talking about capital raising or financing, but about an agreement. If the plan was to further develop the platform alone, the focus would be on capital, organization, and study plans. Not on the fact that there ”of course” must be an agreement behind new studies. Ulrich's statement does not say whether the agreement will be an acquisition or a partnership, but it says something important about the strategic direction the management has chosen. There are really only two possibilities: 💎 1. Acquisition 💎 2. Partnership And precisely for this reason, the discussion about a share issue of DKK 20-30 million seems somewhat uninteresting. The question is no longer whether the platform should be further developed alone, but which of the 2 strategies the management has chosen. Here I will refer to my post on June 1, where I argued that an acquisition with 90-95% probability is most realistic. I still believe that we will see 2 reratings of the case. The first with uTREAT topline in Q3 (my guess is by mid-July at the latest). The second with an acquisition (or a partnership agreement), which will be the really big one. With an acquisition, all asymmetry in the case disappears. 🔥 The recent stock fluctuations after readout absolutely change NOTHING about the case, on the contrary, as uncertainty has been removed. The interesting thing is data and the strategic clarification. Readout: it works! Topline: how well does it work? Data is King - we need to see it! ⚡
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
18 päivää sitten
‧43 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·12 t sittenSell recommendation?·10 t sittenAre you crazy? I am not selling a single one. Maybe one should buy up and secure an early retirement. 🫡😎
- ·16 t sittenhttps://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-520105-39-00 uTREAT phase 1: hmm...has the page not been updated with the following information: Estimated end of trial date in EU/EEA: 23/07/2026 Then we might potentially get topline data end of July / beginning of August... ?·4 t sitten · MuokattuThe Clinical trail dokumentet has been updated via an SM (Substantial Modification). Curasight sent the SM on 27-02-2026 and it was approved on 24-03-2026 (as stated on the front page, cf.. your link) The only thing that has been changed is the Estimated end of trial date in EU/EEA. It has been changed from 15-05-2026 to 27-07-2026. They have thus moved the end date for the GBM Phase I study by a good 2 months. This is due to the expansion of the study from 60 Gy to 100+ Gy and the number of patients from 6 to 12. The first time we heard about the expansion was on 26-02-2026 at the HCA meeting in connection with the annual report (to my knowledge). Here they show a slide describing the expansions and the guided Topline-results mid- 2026. The day after, they send an SM and then guide read-out in Q2 and Topline in Q3. I will not place too much emphasis on the Estimated end of trial date in relation to when Topline results will actually come, as the date is in no way binding! But it gives an indication of what they believed back ultimo Feb. As previously mentioned, I believe mid/ultimo July, especially because they published read-out data 3 weeks before the deadline. And it is a relatively small cohort, so 6-8 weeks should be sufficient for topline data. And it is somewhat in the same direction as they themselves might have had in mind.....but now we have to see. Data is King - we need to see it! ⚡
- ·3 päivää sitten · MuokattuI have sent some questions to Curasight based on the timeline from the TD Cowen conference in March. Q. concern the capital requirement wish for 2027, the company's 'catalysts' on the timeline (picture), M&A / Nasdaq elaboration, confirmation of the number of patients for uTREAT Phase 2 (60pers) and Basket trial Phase 1 (up to six persons per indication) etc. The timeline shows a clear strategy, where there is an opportunity to go several ways (but where the highway is called acquisition). I will follow up with answers if I hear from them.·2 päivää sittenSo I quickly got a reply from Ulrich - and on a Sunday too :) And although the answers perhaps leave a lot to be desired, there is still some clarity regarding the - perhaps - upcoming financing, the uTREAT phase 2 / basket trial phase 1 study sizes, etc.. Here are my questions and subsequent answers. (Then you yourselves must assess whether anything useful can be drawn from it or not... :) ) - - - - - Hi Ulrich, Andreas et al. I have now listened to the Q1 presentation at HCA Cap., as well as the TD Cowen presentation a couple of times and now have a couple of questions that I hope you can / are allowed to answer: 1: Is the timeline presented in connection with TD Cowen still valid (see attached image)? -> I.e.: Capital increase ("Fundraising targeted investors USD XXM") comes after topline data for uTREAT phase 1? (I assume it will be a directed issue similar to December 12, 2025) 2:Ulrich; you state in the Q1 presentation that funds need to be raised so that the 2027 plans can be realized. Does the amount only cover uTREAT phase 2, or potentially also Basket trials, phase 1 (+ expenses up to)? (I'm a bit unsure if you only refer to Basket Tr or both programs when you refer in the presentation to "there must be an agreement/(partner) behind the trials"...) 3: TD Cowen presentation: Is the number of patients still correct; i.e. ~60 patients for uTREAT phase 2 and up to 36 patients for Basket Trials, phase 1? 4: TD Cowen presentation: Mid-2027 you mention a catalyst with "M&A and/or Nasdaq listing". If it becomes a Nasdaq listing; Will that mean that you move away from the Spotlight stock exchange and onto a larger one to simultaneously be able to utilize/offer trading via the American stock exchange (will it then be ADR similar to Novo Nordisk??) 5: It seems quite clear that you are focusing/strategizing on being acquired rather than on more partnerships. -> Without going into detail, can you tell if you already have a timely target for when you believe you will be "most valuable"; i.e. when the most opportune time for an acquisition would be? 6: Are you looking into participating in more international conferences later this year? I hope you can answer, if not all, then a couple of the questions. I am quite active in various Curasight forums online (facebook, nordnet, discord) and would like to share your answers, if that's okay with you? Regards Mads - - - Dear Mads, Thank you for your email, your interest in Curasight, and for taking the time to thoroughly review our presentations. I will try to answer your questions within the framework we can communicate publicly. 1 - Timeline and financing: As a general rule, we do not comment on specific timing aspects regarding potential financing transactions beyond what has already been publicly communicated. Our focus remains on creating the greatest possible value through the clinical programs and the expected milestones. 2 - What should future financing cover?: As mentioned in the Q1 presentation, additional capital will primarily be aimed at supporting the company's clinical development plans after the current studies. This includes both further development of the uTREAT® program and potential new clinical initiatives. However, it is too early to comment on the final structure and financing of future studies. 3 - Number of patients in future studies: The patient numbers stated in our latest presentation material still represent our current planning basis. However, final study designs will be determined in dialogue with regulatory authorities and potential collaboration partners. 4 - Nasdaq listing: When we refer to the possibility of a Nasdaq listing, it is a long-term strategic perspective. At present, no decision has been made regarding exchange, structure, or timing, and therefore we cannot comment further on this. 5 - M&A and strategic opportunities: As a listed company, we continuously evaluate all opportunities that can create value for shareholders. This includes partnerships, licensing agreements, financing opportunities, and potential strategic transactions. However, we have not communicated any specific objective or time horizon for a potential corporate transaction. 6 - International conferences: Yes, we continue to expect to participate in relevant international conferences and investor events as our clinical programs develop. Any participations will be communicated via our normal channels. We greatly appreciate the engagement from our shareholders and the many constructive discussions taking place in investor forums. You are naturally welcome to share the above answers, as they are solely based on already publicly disclosed information and general comments. Thank you for your continued support of Curasight – much appreciated. Sincerely / Best regards Ulrich Krasilnikoff CEO – Managing Director Curasight A/S·1 päivä sittenNice with such competent fellow investors, as well as that you also take the time to inform us others.
- ·11.6.🚀 Will a share issue of DKK 20-30 million strengthen the negotiation position? No, Big Pharma knows what it takes to develop a radiopharma platform. They can immediately see through the intention behind a small share issue. The most interesting thing is actually not the share issue, but what Ulrich said about the capital needs in H2: "...of course we will ensure, when we talk about new studies and other things, that there is an agreement behind it of one kind or another, that can carry it through." He is not talking about capital raising or financing, but about an agreement. If the plan was to further develop the platform alone, the focus would be on capital, organization, and study plans. Not on the fact that there ”of course” must be an agreement behind new studies. Ulrich's statement does not say whether the agreement will be an acquisition or a partnership, but it says something important about the strategic direction the management has chosen. There are really only two possibilities: 💎 1. Acquisition 💎 2. Partnership And precisely for this reason, the discussion about a share issue of DKK 20-30 million seems somewhat uninteresting. The question is no longer whether the platform should be further developed alone, but which of the 2 strategies the management has chosen. Here I will refer to my post on June 1, where I argued that an acquisition with 90-95% probability is most realistic. I still believe that we will see 2 reratings of the case. The first with uTREAT topline in Q3 (my guess is by mid-July at the latest). The second with an acquisition (or a partnership agreement), which will be the really big one. With an acquisition, all asymmetry in the case disappears. 🔥 The recent stock fluctuations after readout absolutely change NOTHING about the case, on the contrary, as uncertainty has been removed. The interesting thing is data and the strategic clarification. Readout: it works! Topline: how well does it work? Data is King - we need to see it! ⚡
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 478 | NON | NON | ||
| 1 222 | NON | NON | ||
| 24 | NON | NON | ||
| 1 567 | SSWM | NON | ||
| 109 | NON | NON |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
2026 Q1 -tulosraportti
18 päivää sitten
‧43 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·12 t sittenSell recommendation?·10 t sittenAre you crazy? I am not selling a single one. Maybe one should buy up and secure an early retirement. 🫡😎
- ·16 t sittenhttps://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-520105-39-00 uTREAT phase 1: hmm...has the page not been updated with the following information: Estimated end of trial date in EU/EEA: 23/07/2026 Then we might potentially get topline data end of July / beginning of August... ?·4 t sitten · MuokattuThe Clinical trail dokumentet has been updated via an SM (Substantial Modification). Curasight sent the SM on 27-02-2026 and it was approved on 24-03-2026 (as stated on the front page, cf.. your link) The only thing that has been changed is the Estimated end of trial date in EU/EEA. It has been changed from 15-05-2026 to 27-07-2026. They have thus moved the end date for the GBM Phase I study by a good 2 months. This is due to the expansion of the study from 60 Gy to 100+ Gy and the number of patients from 6 to 12. The first time we heard about the expansion was on 26-02-2026 at the HCA meeting in connection with the annual report (to my knowledge). Here they show a slide describing the expansions and the guided Topline-results mid- 2026. The day after, they send an SM and then guide read-out in Q2 and Topline in Q3. I will not place too much emphasis on the Estimated end of trial date in relation to when Topline results will actually come, as the date is in no way binding! But it gives an indication of what they believed back ultimo Feb. As previously mentioned, I believe mid/ultimo July, especially because they published read-out data 3 weeks before the deadline. And it is a relatively small cohort, so 6-8 weeks should be sufficient for topline data. And it is somewhat in the same direction as they themselves might have had in mind.....but now we have to see. Data is King - we need to see it! ⚡
- ·3 päivää sitten · MuokattuI have sent some questions to Curasight based on the timeline from the TD Cowen conference in March. Q. concern the capital requirement wish for 2027, the company's 'catalysts' on the timeline (picture), M&A / Nasdaq elaboration, confirmation of the number of patients for uTREAT Phase 2 (60pers) and Basket trial Phase 1 (up to six persons per indication) etc. The timeline shows a clear strategy, where there is an opportunity to go several ways (but where the highway is called acquisition). I will follow up with answers if I hear from them.·2 päivää sittenSo I quickly got a reply from Ulrich - and on a Sunday too :) And although the answers perhaps leave a lot to be desired, there is still some clarity regarding the - perhaps - upcoming financing, the uTREAT phase 2 / basket trial phase 1 study sizes, etc.. Here are my questions and subsequent answers. (Then you yourselves must assess whether anything useful can be drawn from it or not... :) ) - - - - - Hi Ulrich, Andreas et al. I have now listened to the Q1 presentation at HCA Cap., as well as the TD Cowen presentation a couple of times and now have a couple of questions that I hope you can / are allowed to answer: 1: Is the timeline presented in connection with TD Cowen still valid (see attached image)? -> I.e.: Capital increase ("Fundraising targeted investors USD XXM") comes after topline data for uTREAT phase 1? (I assume it will be a directed issue similar to December 12, 2025) 2:Ulrich; you state in the Q1 presentation that funds need to be raised so that the 2027 plans can be realized. Does the amount only cover uTREAT phase 2, or potentially also Basket trials, phase 1 (+ expenses up to)? (I'm a bit unsure if you only refer to Basket Tr or both programs when you refer in the presentation to "there must be an agreement/(partner) behind the trials"...) 3: TD Cowen presentation: Is the number of patients still correct; i.e. ~60 patients for uTREAT phase 2 and up to 36 patients for Basket Trials, phase 1? 4: TD Cowen presentation: Mid-2027 you mention a catalyst with "M&A and/or Nasdaq listing". If it becomes a Nasdaq listing; Will that mean that you move away from the Spotlight stock exchange and onto a larger one to simultaneously be able to utilize/offer trading via the American stock exchange (will it then be ADR similar to Novo Nordisk??) 5: It seems quite clear that you are focusing/strategizing on being acquired rather than on more partnerships. -> Without going into detail, can you tell if you already have a timely target for when you believe you will be "most valuable"; i.e. when the most opportune time for an acquisition would be? 6: Are you looking into participating in more international conferences later this year? I hope you can answer, if not all, then a couple of the questions. I am quite active in various Curasight forums online (facebook, nordnet, discord) and would like to share your answers, if that's okay with you? Regards Mads - - - Dear Mads, Thank you for your email, your interest in Curasight, and for taking the time to thoroughly review our presentations. I will try to answer your questions within the framework we can communicate publicly. 1 - Timeline and financing: As a general rule, we do not comment on specific timing aspects regarding potential financing transactions beyond what has already been publicly communicated. Our focus remains on creating the greatest possible value through the clinical programs and the expected milestones. 2 - What should future financing cover?: As mentioned in the Q1 presentation, additional capital will primarily be aimed at supporting the company's clinical development plans after the current studies. This includes both further development of the uTREAT® program and potential new clinical initiatives. However, it is too early to comment on the final structure and financing of future studies. 3 - Number of patients in future studies: The patient numbers stated in our latest presentation material still represent our current planning basis. However, final study designs will be determined in dialogue with regulatory authorities and potential collaboration partners. 4 - Nasdaq listing: When we refer to the possibility of a Nasdaq listing, it is a long-term strategic perspective. At present, no decision has been made regarding exchange, structure, or timing, and therefore we cannot comment further on this. 5 - M&A and strategic opportunities: As a listed company, we continuously evaluate all opportunities that can create value for shareholders. This includes partnerships, licensing agreements, financing opportunities, and potential strategic transactions. However, we have not communicated any specific objective or time horizon for a potential corporate transaction. 6 - International conferences: Yes, we continue to expect to participate in relevant international conferences and investor events as our clinical programs develop. Any participations will be communicated via our normal channels. We greatly appreciate the engagement from our shareholders and the many constructive discussions taking place in investor forums. You are naturally welcome to share the above answers, as they are solely based on already publicly disclosed information and general comments. Thank you for your continued support of Curasight – much appreciated. Sincerely / Best regards Ulrich Krasilnikoff CEO – Managing Director Curasight A/S·1 päivä sittenNice with such competent fellow investors, as well as that you also take the time to inform us others.
- ·11.6.🚀 Will a share issue of DKK 20-30 million strengthen the negotiation position? No, Big Pharma knows what it takes to develop a radiopharma platform. They can immediately see through the intention behind a small share issue. The most interesting thing is actually not the share issue, but what Ulrich said about the capital needs in H2: "...of course we will ensure, when we talk about new studies and other things, that there is an agreement behind it of one kind or another, that can carry it through." He is not talking about capital raising or financing, but about an agreement. If the plan was to further develop the platform alone, the focus would be on capital, organization, and study plans. Not on the fact that there ”of course” must be an agreement behind new studies. Ulrich's statement does not say whether the agreement will be an acquisition or a partnership, but it says something important about the strategic direction the management has chosen. There are really only two possibilities: 💎 1. Acquisition 💎 2. Partnership And precisely for this reason, the discussion about a share issue of DKK 20-30 million seems somewhat uninteresting. The question is no longer whether the platform should be further developed alone, but which of the 2 strategies the management has chosen. Here I will refer to my post on June 1, where I argued that an acquisition with 90-95% probability is most realistic. I still believe that we will see 2 reratings of the case. The first with uTREAT topline in Q3 (my guess is by mid-July at the latest). The second with an acquisition (or a partnership agreement), which will be the really big one. With an acquisition, all asymmetry in the case disappears. 🔥 The recent stock fluctuations after readout absolutely change NOTHING about the case, on the contrary, as uncertainty has been removed. The interesting thing is data and the strategic clarification. Readout: it works! Topline: how well does it work? Data is King - we need to see it! ⚡
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 478 | NON | NON | ||
| 1 222 | NON | NON | ||
| 24 | NON | NON | ||
| 1 567 | SSWM | NON | ||
| 109 | NON | NON |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt